SteelPeak Wealth LLC Buys Shares of 55,795 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

SteelPeak Wealth LLC purchased a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 55,795 shares of the company's stock, valued at approximately $1,617,000. SteelPeak Wealth LLC owned approximately 0.12% of Amphastar Pharmaceuticals at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in Amphastar Pharmaceuticals during the fourth quarter valued at approximately $38,000. GAMMA Investing LLC grew its holdings in Amphastar Pharmaceuticals by 46.6% in the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock valued at $39,000 after purchasing an additional 424 shares during the period. Tower Research Capital LLC TRC grew its holdings in Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares during the period. Huntington National Bank grew its holdings in Amphastar Pharmaceuticals by 36.9% in the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after purchasing an additional 361 shares during the period. Finally, TD Private Client Wealth LLC grew its holdings in Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after purchasing an additional 388 shares during the period. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH traded down $0.77 during trading on Tuesday, reaching $21.18. The stock had a trading volume of 504,340 shares, compared to its average volume of 496,969. The business has a fifty day moving average price of $24.53 and a 200-day moving average price of $28.21. The stock has a market cap of $998.43 million, a PE ratio of 7.67, a PEG ratio of 5.64 and a beta of 0.72. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.02 and a current ratio of 2.95. Amphastar Pharmaceuticals, Inc. has a 1-year low of $21.16 and a 1-year high of $53.96.

Analyst Ratings Changes

Several brokerages have commented on AMPH. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Finally, Wells Fargo & Company lowered their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $32.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.